Biohit (BIOBV.HE) Stock Analysis & AI Equity Report
Biohit (BIOBV.HE) overview
Biohit (BIOBV.HE) stock analysis and AI equity research. For the latest completed financial year, 2024, Biohit reported revenue of EUR 14.3m and operating profit of EUR 2.6m; the year-end share price was N/A and market capitalisation was N/A. Biohit is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Biohit's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-06-13. Data will be refreshed during report generation.
About Biohit
Biohit Oyj is a Finnish biotechnology company focused on developing, manufacturing and marketing diagnostic products and analysis systems for gastrointestinal diseases, along with health-promoting products. Its portfolio includes the GastroPanel® diagnostic test, Acetium® products that bind acetaldehyde, and laboratory tests and instruments. The company sells through subsidiaries and a global network of distributors and partners.
Generate the Biohit report
Biohit is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Biohit and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.